Abstract | INTRODUCTION: AREAS COVERED: This paper reviews the available literature on the use of alfuzosin in the treatment of storage symptoms suggestive of OAB. Additionally, the role of α-adrenoreceptor antagonists in the treatment of OAB is reviewed, based on pathophysiology. EXPERT OPINION: Although alfuzosin is effective against storage symptoms, it does not improve them in all patients with OAB. It is likely that alternative types of therapy, such as antimuscrarinics, need to be co-administered to patients with residual storage symptoms after alfuzosin administration. Alfuzosin can decrease the risk of adverse events associated with antimuscarinics. The sequential use of alfuzosin and antimuscarinics appears to be an appropriate strategy for the treatment of storage symptoms suggestive of OAB related to BOO.
|
Authors | Kang Jun Cho, Joon Chul Kim |
Journal | Expert opinion on pharmacotherapy
(Expert Opin Pharmacother)
Vol. 13
Issue 8
Pg. 1143-51
(Jun 2012)
ISSN: 1744-7666 [Electronic] England |
PMID | 22594844
(Publication Type: Journal Article, Review)
|
Chemical References |
- Adrenergic alpha-Antagonists
- Quinazolines
- alfuzosin
|
Topics |
- Adrenergic alpha-Antagonists
(therapeutic use)
- Animals
- Humans
- Quinazolines
(therapeutic use)
- Urinary Bladder, Overactive
(drug therapy)
|